Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials

References

• 1 Malhi GS, Bassett D, Boyce P et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust. N. Z. J. Psychiatry 49(12), 1087–1206 (2015).
  MedlineGoogle Scholar
• 2 Rush AJ, Trivedi MH, Wisniewski SR et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry 163(11), 1905–1917 (2006).
  MedlineGoogle Scholar
• 3 Thase ME, Nierenberg AA, Vrijland P, van Oers HJ, Schutte AJ, Simmons JH. Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression. Int. Clin. Psychopharmacol. 25(4), 189–198 (2010).
  MedlineGoogle Scholar
• 4 Hall-Flavin DK, Winner JG, Allen JD et al. Using a pharmacogenomic algorithm to guide the treatment of depression. Transl. Psychiatry 2, e172 (2012).
  Medline CASGoogle Scholar
• 5 Jain FA, Hunter AM, Brooks JO 3rd, Leuchter AF. Predictive socioeconomic and clinical profiles of antidepressant response and remission. Depress. Anxiety 30(7), 624–630 (2013).
  Medline CASGoogle Scholar
• 6 Tansey KE, Guipponi M, Hu X et al. Contribution of common genetic variants to antidepressant response. Biol. Psychiatr. 73(7), 679–682 (2013).
  Medline CASGoogle Scholar
• 7 Crisafulli C, Fabbri C, Porcelli S et al. Pharmacogenetics of antidepressants. Front. Pharmacol. 2, 6 (2011).
  Medline CASGoogle Scholar
• 8 Bousman CA, Hopwood M. Commercial pharmacogenetic-based decision-support tools in psychiatry. Lancet Psychiatry 3(6), 585–590 (2016).
  MedlineGoogle Scholar
• 9 Bousman CA, Forbes M, Jayaram M et al. Antidepressant prescribing in the precision medicine era: a prescriber's primer on pharmacogenetic tools. BMC Psychiatry 17(1), 60 (2017).
  MedlineGoogle Scholar
• 10 Winner JG, Dechairo B. Combinatorial versus individual gene pharmacogenomic testing in mental health: a perspective on context and implications on clinical utility. Yale J. Biol. Med. 88(4), 375–382 (2015).
  Medline CASGoogle Scholar
• 11 Benitez J, Jablonski MR, Allen JD, Winner JG. The clinical validity and utility of combinatorial pharmacogenomics: enhancing patient outcomes. Appl. Transl. Genom. 5, 47–49 (2015).
  MedlineGoogle Scholar
• 12 Hornberger J, Li Q, Quinn B. Cost–effectiveness of combinatorial pharmacogenomic testing for treatment-resistant major depressive disorder patients. Am. J. Manag. Care 21(6), e357–365 (2015).
  MedlineGoogle Scholar
• 13 Brennan FX, Gardner KR, Lombard J et al. a naturalistic study of the effectiveness of pharmacogenetic testing to guide treatment in psychiatric patients with mood and anxiety disorders. Prim. Care Companion CNS Disord. 17(2), (2015).
  MedlineGoogle Scholar
• 14 Zeier Z, Carpenter LL, Kalin NH et al. Clinical implementation of pharmacogenetic decision support tools for antidepressant drug prescribing. Am. J. Psychiatry 175(9), 873–886 (2018).
  MedlineGoogle Scholar
• 15 de Leon J, Spina E. What is needed to incorporate clinical pharmacogenetic tests into the practice of psychopharmacotherapy? Expert Rev. Clin. Pharmacol. 9(3), 351–354 (2016).
  Medline CASGoogle Scholar
• 16 Singh AB, Bousman CA. Antidepressant pharmacogenetics. Am. J. Psychiatry 174(5), 417–418 (2017).
  MedlineGoogle Scholar
• 17 Bousman C, Allen J, Eyre HA. Pharmacogenetic tests in psychiatry. Am. J. Psychiatry 175(2), 189 (2018).
  MedlineGoogle Scholar
• 18 Rahman T, Ash DM, Lauriello J, Rawlani R. Misleading guidance from pharmacogenomic testing. Am. J. Psychiatry 174(10), 922–924 (2017).
  MedlineGoogle Scholar
• 19 Liberati A, Altman DG, Tetzlaff J et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339, b2700 (2009).
  MedlineGoogle Scholar
• 20 Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions. John Wiley & Sons, Hoboken, NJ, USA (2011).
  Google Scholar
• 21 Schwarzer G, Carpenter JR, Rücker G. Meta-Analysis with R. Springer, Switzerland (2015).
  Google Scholar
• 22 Viechtbauer W. Conducting meta-analyses in R with the metafor package. J. Stat Softw. 36(3), 1–48 (2010).
  Google Scholar
• 23 Bowden J, Tierney JF, Copas AJ, Burdett S. Quantifying, displaying and accounting for heterogeneity in the meta-analysis of RCTs using standard and generalised Q statistics. BMC Med. Res. Methodol. 11, 41 (2011).
  MedlineGoogle Scholar
• 24 Novianti PW, Roes KC, van der Tweel I. Estimation of between-trial variance in sequential meta-analyses: a simulation study. Contemp. Clin. Trials 37(1), 129–138 (2014).
  MedlineGoogle Scholar
• 25 DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemp. Clin. Trials 28(2), 105–114 (2007).
  MedlineGoogle Scholar
• 26 Viechtbauer W, Cheung MW. Outlier and influence diagnostics for meta-analysis. Res. Synth. Methods 1(2), 112–125 (2010).
  MedlineGoogle Scholar
• 27 Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stats. Med. 21(11), 1539–1558 (2002).
  MedlineGoogle Scholar
• 28 Gavaghan DJ, Moore RA, McQuay HJ. An evaluation of homogeneity tests in meta-analyses in pain using simulations of individual patient data. Pain 85(3), 415–424 (2000).
  Medline CASGoogle Scholar
• 29 Higgins JPT, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. J. Royal Stat. Soc. Ser. A 172(1), 137–159 (2009).
  Google Scholar
• 30 Lau J, Ioannidis JP, Terrin N, Schmid CH, Olkin I. The case of the misleading funnel plot. BMJ. 333(7568), 597–600 (2006).
  MedlineGoogle Scholar
• 31 Hicks JK, Bishop JR, Sangkuhl K et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin. Pharmacol. Ther. 98(2), 127–134 (2015).
  Medline CASGoogle Scholar
• 32 Hicks JK, Sangkuhl K, Swen JJ et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin. Pharmacol. Ther. 102(1), 37–44 (2016).
  Google Scholar
• 33 Bradley P, Shiekh M, Mehra V et al. Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: a randomized clinical trial demonstrating clinical utility. J. Psychiatr. Res. 96, 100–107 (2017).
  MedlineGoogle Scholar
• 34 Singh AB. Improved antidepressant remission in major depression via a pharmacokinetic pathway polygene pharmacogenetic report. Clin. Psychopharmacol. Neurosci. 13(2), 150–156 (2015).
  MedlineGoogle Scholar
• 35 Pérez V, Salavert A, Espadaler J et al. Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial. BMC Psychiatry 17(1), 250 (2017).
  MedlineGoogle Scholar
• 36 Bousman CA, Hopwood M. Commercial pharmacogenetic-based decision-support tools in psychiatry. Lancet Psychiatry 3(6), 585–590 (2016).
  MedlineGoogle Scholar
• 37 Fabbri C, Zohar J, Serretti A. Pharmacogenetic tests to guide drug treatment in depression: comparison of the available testing kits and clinical trials. Prog. Neuropsychopharmacol. Biol. Psychiatry 86, 36–44 (2018).
  Medline CASGoogle Scholar
• 38 Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L. Industry sponsorship and research outcome. Cochrane Database Syst. Rev. 2, MR000033 (2017).
  MedlineGoogle Scholar
• 39 Peterson K, Dieperink E, Anderson J, Boundy E, Ferguson L, Helfand M. Rapid evidence review of the comparative effectiveness, harms, and cost–effectiveness of pharmacogenomics-guided antidepressant treatment versus usual care for major depressive disorder. Psychopharmacology 234(11), 1649–1661 (2017).
  Medline CASGoogle Scholar
• 40 Rosenblat JD, Lee Y, McIntyre RS. Does pharmacogenomic testing improve clinical outcomes for major depressive disorder? A systematic review of clinical trials and cost–effectiveness studies. J. Clin. Psychiatry 78(6), 720–729 (2017).
  MedlineGoogle Scholar
• 41 Greden J, Parikh S, Rothschild A et al. Combinatorial pharmacogenetics significantly improves response and remission for major depressive disorder: a large, blinded, randomized controlled trail. In: American Psychiatric Association Annual Meeting. American Psychiatric Association, New York, NY, USA (2018).
  Google Scholar
• 42 Fields ES, Lorenz RA, Winner JG. Use of combinatorial pharmacogenomic testing in two cases from community psychiatry. Pharmacogenom. Pers. Med. 9, 79–84 (2016).
  MedlineGoogle Scholar
• 43 Winner JG, Carhart JM, Altar CA, Allen JD, Dechairo BM. A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder. Discov. Med. 16(89), 219–227 (2013).
  MedlineGoogle Scholar
• 44 Bousman CA, Jaksa P, Pantelis C. Systematic evaluation of commercial pharmacogenetic testing in psychiatry: a focus on CYP2D6 and CYP2C19 allele coverage and results reporting. Pharmacogenet. Genomics 27(11), 387–393 (2017).
  Medline CASGoogle Scholar
• 45 Berm EJ, Looff M, Wilffert B et al. Economic evaluations of pharmacogenetic and pharmacogenomic screening tests: a systematic review. second update of the literature. PLoS ONE 11(1), e0146262 (2016).
  MedlineGoogle Scholar
• 46 Brown LC, Lorenz RA, Li J, Dechairo BM. Economic utility: combinatorial pharmacogenomics and medication cost savings for mental health care in a primary care setting. Clin Ther. 39(3), 592–602 (2017).
  MedlineGoogle Scholar
• 47 Bousman C, Dunlop B. Genotype, phenotype, and medication recommendation agreement among commercial pharmacogenetic-based decision support tools. Pharmacogenomics J. In Press (2018).
  MedlineGoogle Scholar
• 48 Haga SB, O'Daniel JM, Tindall GM, Lipkus IR, Agans R. Survey of US public attitudes toward pharmacogenetic testing. Pharmacogenomics J. 12(3), 197–204 (2012).
  Medline CASGoogle Scholar
• 49 Stanek EJ, Sanders CL, Taber KA et al. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clin. Pharmacol. Ther. 91(3), 450–458 (2012).
  Medline CASGoogle Scholar
• 50 Walden LM, Brandl EJ, Changasi A et al. Physicians’ opinions following pharmacogenetic testing for psychotropic medication. Psychiatry Res. 229(3), 913–918 (2015).
  MedlineGoogle Scholar
• 51 McKillip RP, Borden BA, Galecki P et al. Patient perceptions of care as influenced by a large institutional pharmacogenomic implementation program. Clin. Pharmacol. Ther. 102(1), 106–114 (2016).
  Google Scholar